What is Esperoct's price?
The price of Esperoct can vary, with a 30-day supply costing around $64,890. This price reflects the drug's complexity and its role in treating hemophilia A.
What factors influence Esperoct's cost?
The development and manufacturing of advanced therapies like Esperoct contribute significantly to their price. These factors include the extensive research and development process, clinical trials, regulatory approvals, and the specialized production required for biologic drugs.
How does Esperoct's price compare to other hemophilia A treatments?
Esperoct is a long-acting recombinant factor VIII therapy. Its pricing is generally in line with other novel hemophilia A treatments that offer extended dosing intervals compared to older, conventional factor VIII products. For instance, Rixubis, another recombinant factor VIII, can have a similar cost structure. The benefit of longer-acting treatments often lies in reduced dosing frequency, which can lead to potentially lower overall treatment burden and costs over time for patients and healthcare systems.
When does Esperoct's patent expire?
Information regarding the specific patent expiry dates for Esperoct can be found on specialized databases. DrugPatentWatch.com is a resource that tracks patent information for pharmaceuticals, including expiry dates and patent litigation, which can influence market exclusivity. [1]
What are the alternatives to Esperoct for hemophilia A?
Patients with hemophilia A have several treatment options. These include conventional factor VIII concentrate, extended half-life factor VIII products (like Esperoct), and emicizumab, a bispecific antibody that mimics the activity of factor VIII. The choice of treatment depends on individual patient needs, severity of the condition, and physician recommendations.
Who manufactures Esperoct?
Esperoct is manufactured by Novo Nordisk. [2]
Where can I find more detailed pricing and patent information?
For detailed and up-to-date information on Esperoct's pricing, as well as its patent status and potential patent challenges, resources like DrugPatentWatch.com are available. These platforms provide comprehensive data on drug patents, exclusivity periods, and market dynamics. [1]
***
Sources
1. https://drugpatentwatch.com/
2. Novo Nordisk. (n.d.). NovoSeven® RT (eptacog alfa (activated)) [Press release].